omeprazole has been researched along with midazolam in 122 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.82) | 18.2507 |
| 2000's | 22 (18.03) | 29.6817 |
| 2010's | 72 (59.02) | 24.3611 |
| 2020's | 27 (22.13) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Dai, R; Liu, Y; She, M; Wu, Z | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
| Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL | 1 |
| Klotz, U; Li, G | 1 |
| Bertino, JS; Bleakley, JF; Gaedigk, A; Gotschall, R; Kearns, GL; Kim, JS; Leeder, JS; Nafziger, AN; Streetman, DS | 1 |
| Chen, XP; He, N; Huang, SL; Ou-Yang, DS; Tan, ZR; Zhou, HH; Zhu, B | 1 |
| Bertino, JS; Chainuvati, S; Gaedigk, A; Kashuba, AD; Kearns, GL; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Zhang, Y | 1 |
| Cherkaoui, S; Daali, Y; Dayer, P; Jerdi, MC; Oestreicher, MK | 1 |
| Frerichs, VA; Haas, CE; Zaranek, C | 1 |
| Booker, BM; Brazeau, D; Cloen, D; Frerichs, V; Frye, RF; Haas, CE; Kufel, T; Zaranek, C | 1 |
| Bertino, JS; Gaedigk, A; Kashuba, AD; Kearns, G; Leeder, JS; Nafziger, AN; Rowland, E; Sellers, E; Shelepova, T; Victory, J; Zhang, Y | 1 |
| Adkison, KK; Berrey, MM; Bertino, JS; Borland, J; Fang, L; Johnson, BM; Lou, Y; Nafziger, AN; Piscitelli, SC; Song, IH | 1 |
| Baxter-Meheux, F; Blake, MJ; Eron, JJ; Gaver, VE; Kashuba, AD; Klein, CE; Patterson, KB; Rezk, NL; Rublein, JC; Yeh, RF | 1 |
| Cha, IJ; Liu, KH; Ryu, JY; Shin, JG; Shon, JH; Song, IS; Sunwoo, YE | 1 |
| Coelho, EB; Lanchote, VL; Moussa, SA; Rocha, A | 1 |
| Chem, MC; Chetty, M; Ghassabian, S; Glen, J; McLachlan, AJ; Murray, M; Rahme, J; Ramzan, I; Stankovic, Z; Tattam, BN | 1 |
| Cho, JY; Hong, JH; Jang, IJ; Kim, BH; Kim, J; Kim, KP; Lim, KS; Shin, SG; Yi, S; Yu, KS | 1 |
| Gibson, R; Ndikum-Moffor, F; Ogilvie, BW; Paris, BL; Parkinson, A; Scheinkoenig, JA | 1 |
| Collins, DA; Deng, Y; Jenkins, J; Kitchen, VS; Williams, D | 1 |
| Boulenc, X; Brian, W; Donazzolo, Y; Poitiers, F; Santoni, A; Turpault, S; Van Horn, R | 1 |
| Bertelsen, K; Guo, P; Han, F; Huang, MQ; Lin, ZJ; Weng, N; Zhang, W; Zhao, H | 1 |
| Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L | 1 |
| Anand, S; Burris, H; Kurzrock, R; Lewis, N; Reid, T; Tan, EY; Tsimberidou, AM; Uehara, C; Urban, P | 1 |
| Chen, Y; Guo, Y; Klaassen, CD; Tan, ZR; Zhou, HH | 1 |
| Auwärter, V; Dresen, S; Lutz-Bonengel, S; Naue, J; Wohlfarth, A | 1 |
| Chen, Y; Kang, Z; Ouyang, DS; Tan, ZR; Yan, J; Yang, GP; Zhou, G | 1 |
| Takayanagi, R; Teramoto, S; Uotsu, N; Yamada, M; Yamada, Y; Yamasaki, I | 1 |
| Iwasaki, K; Izumi, H; Kusumoto, S; Mogi, M; Murayama, N; Shimizu, M; Takehara, H; Toda, A; Utoh, M; Yamazaki, H | 1 |
| Chalasani, N; Hall, SD; Jones, DR; Mattar, S; Tandra, S; Vuppalanchi, R | 1 |
| Akamatsu, T; Chida, K; Inui, N; Karayama, M; Namiki, N; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Cargill, A; Haberer, LJ; McCarthy, L; McSherry, I | 1 |
| Aharchi, F; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Onkelinx, J; Peeters, M; Stevens, T; Van Solingen-Ristea, RM | 1 |
| Chen, M; Chen, X; Han, A; Lin, G; Ma, J; Wang, X; Wen, C; Yang, X | 1 |
| Namiki, N; Tanaka, S; Uchida, S | 1 |
| Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Staub, C; Walder, B | 1 |
| Davis, C; Foti, RS; Isoherranen, N; Kunze, KL; Lutz, JD; Sager, JE | 1 |
| Bosilkovska, M; Daali, Y; Dayer, P; Déglon, J; Desmeules, JA; Rebsamen, M; Samer, CF; Staub, C; Walder, B | 1 |
| Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD | 1 |
| Johansson, S; Leese, PT; Li, Y; Lisbon, E; Martin, P; Mathews, D; Oliver, S; Read, J; Steinberg, M | 1 |
| Ikeda, K; Kim, S; Koyanagi, T; Murayama, N; Nakanishi, Y; Uehara, S; Uno, Y; Utoh, M; Yamaura, Y; Yamazaki, H; Yano, K | 1 |
| Cao, X; Huang, Y; Lan, YY; Li, YJ; Liao, SG; Liu, Y; Lu, Y; Tang, L; Wang, AM; Wang, YL; Zheng, L | 1 |
| Lin, C; Lin, G; Ma, J; Wang, S; Wang, X; Zhang, M; Zhang, Q; Zhou, Y | 1 |
| Gu, N; Kong, HR; Wang, M; Zhou, MT; Zhu, HD | 1 |
| Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathôt, RA; Romijn, JA; Soeters, MR; van Nierop, FS | 1 |
| Corcoran, M; Ermer, J; Martin, P | 1 |
| Almeida, R; Barral, A; Barral-Netto, M; da Silva, AM; Lanchote, VL; Marques, MP; Moraes, NV; Souza, TM; Suarez-Kurtz, G | 1 |
| Chen, D; Davis, HM; de Vries, DE; Leon, F; Marciniak, SJ; Xu, Z; Zhou, H; Zhuang, Y | 1 |
| Murayama, N; Shida, S; Shimizu, M; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Inoue, T; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Dai, GL; Ju, WZ; Rong, N; Sun, BT; Tan, HS; Zang, YX; Zhao, WZ | 1 |
| Berger, B; Derungs, A; Donzelli, M; Haschke, M; Krähenbühl, S; Noppen, C | 1 |
| Bénech, H; Lenuzza, N; Nguyen, TT; Pruvost, A | 1 |
| Hellum, B; Nilsen, OG; Spigset, O; Thu, OK | 1 |
| Shida, S; Yamazaki, H | 1 |
| Chen, RJ; Ge, NY; Hao, C; Zhang, DF; Zhang, Y; Zhang, YT; Zhu, GH | 1 |
| Kawano, M; Mitsui, M; Sasaki, E; Shimizu, M; Suemizu, H; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Bosilkovska, M; Daali, Y; Déglon, J; Desmeules, J; Samer, C; Thomas, A; Walder, B | 1 |
| Fang, Y; Gao, J; Gao, N; He, XP; Jia, LJ; Jin, H; Qiao, HL; Tian, X; Wen, Q; Zhang, YF; Zhou, J | 1 |
| Achterbergh, R; Klümpen, HJ; Lammers, LA; Mathôt, RA; Romijn, JA; Soeters, MR; van Nierop, S | 1 |
| Achterbergh, R; Boelen, A; de Vries, EM; Klümpen, HJ; Lammers, LA; Mathot, RA; Romijn, JA | 1 |
| Jeon, JY; Kim, DS; Kim, MG; Kim, Y | 1 |
| Armani, S; Chun, DY; Darstein, C; Einolf, HJ; Gu, H; Kulkarni, S; Sauter, N; Ting, L; Tripathi, AP; Wang, L; Zhu, B | 1 |
| Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA; van Schaik, RHN | 1 |
| Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Edwards, JE; Eliot, L; Karan, S; MacConell, L; Parkinson, A | 1 |
| Gajee, R; Papadopoulos, KP; Puzanov, I; Strickler, JH; Tachibana, M; Wang, Y; Zahir, H | 1 |
| Achterbergh, R; Lammers, LA; Mathôt, RAA; Romijn, JA | 1 |
| Gong, Z; Huang, J; Li, Y; Liu, C; Liu, T; Lu, Y; Pan, J; Sun, J; Wang, Y; Zheng, J; Zheng, L | 1 |
| Mangoni, AA; Rowland, A; Sorich, MJ; van Dyk, M; Warncken, D | 1 |
| Arakawa, H; Itoh, M; Kojima, H; Koyama, S; Masuda, N; Ogihara, T; Yano, K | 1 |
| Murayama, N; Yamazaki, H | 1 |
| Bailey-Smith, C; Bodrug, I; Cheng, A; Glasgow, XS; Hussain, A; Iwamoto, M; Khalilieh, S; Levine, V; Martinho, M; Mekokishvili, L; Montgomery, D; Shaw, PM | 1 |
| Dai, GL; He, SF; Hu, HB; Ju, WZ; Zhang, Q; Zhu, LJ | 1 |
| Choi, MK; Choi, WG; Han, YH; Heo, JK; Jo, J; Kang, WY; Lee, HS; Lee, HW; Lee, S; Liu, KH; Ohk, B; Seong, SJ; Song, IS; Yoon, YR | 1 |
| Chen, RJ; Dong, YY; Huang, CK; Lin, ZF; Sun, R; Sun, W; Wang, Z; Ye, WJ; Zhang, XD | 1 |
| Cintra, MACT; Coelho, EB; Cusinato, DAC; Filgueira, GCO; Lanchote, VL; Rocha, A | 1 |
| Camez, A; Cheng, L; Ignatenko, S; Khatri, A; Othman, AA; Pang, Y | 1 |
| Collins, C; Ernault, E; Fuhr, R; Gangaram-Panday, S; Passier, P; Treijtel, N; van Bruijnsvoort, M | 1 |
| Ducray, PS; Endo-Tsukude, C; Gardner, I; Gill, KL; Hatley, OJ; Machavaram, KK; Parrott, N; Terao, K | 1 |
| Chung, JY; Hatley, O; Kim, Y; Lee, H; Lee, HA; Rhee, SJ; Yi, S; Yoon, S; Yu, KS | 1 |
| Cho, SA; Kim, WY; Lee, SJ; Lee, SS; Shin, JG; Yi, M; Yoo, SE | 1 |
| Chiasson, JL; Grangeon, A; Gravel, S; Michaud, V; Turgeon, J | 1 |
| Enejosa, JV; Feng, T; Fisniku, O; Mohamed, MF; Othman, AA | 1 |
| Eagles, SK; Gross, AS; McLachlan, AJ; Wang, X | 1 |
| Du, HJ; Lin, YP; Tan, WZ; Tang, BE; Wei, YL; Wu, ML; Ying, XQ | 1 |
| Chen, D; Piantone, A; Sharma, A; Shu, C; Xu, Y; Xu, Z; Zhou, H; Zhu, Y; Zhuang, Y | 1 |
| Krishna, G; LoRusso, PM; Ogasawara, K; Olszanski, AJ; Palmisano, M; Rixe, O; Xu, C; Yin, J | 1 |
| Hakamata, A; Inui, N; Kamiya, C; Katayama, N; Kawakami, J; Miura, M; Namiki, N; Odagiri, K; Tanaka, S; Uchida, S; Watanabe, H | 2 |
| Chenel, M; Gautier-Veyret, E; Payen, L; Simon, F; Stanke-Labesque, F; Tod, M; Truffot, A | 1 |
| Andersson, TB; Artursson, P; Christensen, H; Krogstad, V; Matsson, P; Urdzik, J; Wegler, C | 1 |
| Brantley, SJ; Dai, X; Goulet, MT; Hard, ML; Hitron, M; Karol, MD; McLaughlin, CF | 1 |
| Agarwal, S; Clausen, VA; Harper, P; Najafian, N; Robbie, GJ; Sardh, E; Simon, AR; Vassiliou, D | 1 |
| Balazki, P; Baumgart, J; Beelen, DW; Böhm, S; Hemmelmann, C; Hilger, RA; Martins, FS; Ring, A; Schaller, S | 1 |
| Chen, Y; Miao, X; Wang, L; Zhou, H; Zhou, W | 1 |
| Daali, Y; Desmeules, JA; Lenoir, C; Niederer, A; Rollason, V; Samer, CF | 1 |
| Blank, A; Burhenne, J; Elbe, A; Foerster, KI; Haefeli, WE; Mikus, G; Rose, P | 1 |
| Ang, DSW; Ang, TL; Benech, H; Koo, SH; Lee, EJD; Pruvost, A; Soon, GH | 1 |
| Bachmann, F; Bouitbir, J; Duthaler, U; Grandinetti, T; Haschke, M; Hruz, P; Krähenbühl, S; Pfefferkorn, F; Suenderhauf, C | 1 |
| Chen, LJ; Chen, XP; Chen, Y; Guo, J; Liou, YL; Tan, ZR; Xu, Y; Zhang, SX; Zhang, W; Zhou, HH | 1 |
| Newman, EM; Rowland, A | 1 |
| Chen, SY; Chen, Y; Gong, ZP; Huang, J; Huang, Y; Li, Y; Li, YT; Wang, YL; Yang, HL; Zheng, L | 1 |
| Anliker-Ort, M; Berger, B; Delahaye, S; Dingemanse, J; Janů, L; Kaufmann, P; van den Anker, J | 1 |
| Bansal, S; Paine, MF; Spindle, TR; Thummel, KE; Unadkat, JD; Vandrey, R; Weerts, EM; Zamarripa, CA | 1 |
| Ah-See, ML; Edenfield, WJ; Lewis, LD; Li, Y; Mugundu, GM; Nadeau, L; Någård, M; Ottesen, LH; Safran, HP; Strauss, J; Wise-Draper, T | 1 |
| Fan, Y; Feng, S; Fu, M; Gu, F; Huang, J; Lin, H; Lu, Z; Luo, L; Shen, K; Wu, B | 1 |
| Aarnoutse, RE; Boeree, MJ; Coenen, MJH; Colbers, A; Dawson, R; Diacon, AH; Fuhr, U; Jager, Vd; Narunsky, K; Padayachee, SD; Phillips, PPJ; Stemkens, R; Svensson, EM; Te Brake, LHM; van Beek, SW | 1 |
| Berger, B; Berse, M; Dingemanse, J; Grignaschi, N; Kaufmann, P; Treiber, A | 1 |
2 review(s) available for omeprazole and midazolam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.
Topics: Animals; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Dextromethorphan; Metoprolol; Midazolam; Non-alcoholic Fatty Liver Disease; Omeprazole; Rosiglitazone; Warfarin | 2022 |
40 trial(s) available for omeprazole and midazolam
| Article | Year |
|---|---|
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Topics: Acetyltransferases; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Genotype; Humans; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Phosphodiesterase Inhibitors; Reproducibility of Results; Vitamins; Warfarin; Xanthine Oxidase | 2003 |
Analysis of omeprazole, midazolam and hydroxy-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aryl Hydrocarbon Hydroxylases; Calibration; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Humans; Injections, Intravenous; Mass Spectrometry; Midazolam; Mixed Function Oxygenases; Omeprazole; Reproducibility of Results; Time Factors | 2005 |
Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Gene Expression Regulation, Enzymologic; Humans; Leukocytes, Mononuclear; Male; Midazolam; Omeprazole; Rifampin; RNA, Messenger | 2005 |
Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
Topics: Adult; Arylamine N-Acetyltransferase; Caffeine; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Genotype; Humans; Midazolam; Norgestrel; Omeprazole; Therapeutic Equivalency; Vitamin K; Warfarin; Xanthine Oxidase | 2005 |
Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; CCR5 Receptor Antagonists; Dextromethorphan; Diketopiperazines; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Omeprazole; Piperazines; Spiro Compounds; Warfarin | 2006 |
Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
Topics: Administration, Oral; Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Genotype; Humans; Isoenzymes; Linear Models; Losartan; Male; Midazolam; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymerase Chain Reaction; Reference Values; Time Factors | 2007 |
Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Anticoagulants; Area Under Curve; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Humans; Male; Metabolic Clearance Rate; Midazolam; Omeprazole; Warfarin; Young Adult | 2009 |
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Topics: Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Isoenzymes; Melanoma; Midazolam; Niacinamide; Omeprazole; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Epothilones; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Omeprazole | 2011 |
Repeated administration of berberine inhibits cytochromes P450 in humans.
Topics: Adult; Berberine; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Dextromethorphan; Drug Interactions; Drugs, Chinese Herbal; Enzyme Inhibitors; Humans; Losartan; Male; Midazolam; Omeprazole; Young Adult | 2012 |
Effect of a traditional Chinese medicine Liu Wei Di Huang Wan on the activities of CYP2C19, CYP2D6 and CYP3A4 in healthy volunteers.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; China; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dextromethorphan; Drugs, Chinese Herbal; Genotype; Herb-Drug Interactions; Humans; Male; Midazolam; Omeprazole; Placebos | 2012 |
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Biotransformation; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Dextromethorphan; Diuretics; Excitatory Amino Acid Antagonists; Female; Furosemide; GABA Modulators; Gastric Bypass; Humans; Hypoglycemic Agents; Male; Midazolam; Middle Aged; Omeprazole; Pharmacokinetics; Tandem Mass Spectrometry; Tolbutamide; Young Adult | 2013 |
Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Drug Interactions; Female; Fluorobenzenes; Humans; Liver-Specific Organic Anion Transporter 1; Male; Midazolam; Middle Aged; Neoplasm Proteins; Omeprazole; Organic Anion Transporters; Pioglitazone; Pyrimidines; Receptors, CCR; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones; Young Adult | 2014 |
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Nitriles; Omeprazole; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Theophylline; Warfarin; Young Adult | 2014 |
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Topics: Adult; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Calcium Channel Blockers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Felodipine; Female; Genotype; Humans; Losartan; Male; Midazolam; Omeprazole; Young Adult | 2014 |
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Topics: Adolescent; Adult; Area Under Curve; Digoxin; Drug Interactions; Female; Humans; Male; Metformin; Midazolam; Middle Aged; Omeprazole; Piperidines; Quinazolines; Ranitidine; Young Adult | 2014 |
Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Topics: Adult; Animals; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Fasting; Gene Expression Regulation, Enzymologic; Humans; Liver; Male; Metabolic Clearance Rate; Metoprolol; Midazolam; Omeprazole; Rats, Wistar; Warfarin; Young Adult | 2015 |
Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
Topics: Adult; Area Under Curve; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Lisdexamfetamine Dimesylate; Male; Midazolam; Omeprazole | 2015 |
Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.
Topics: Adolescent; Adult; Brazil; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Leishmaniasis, Visceral; Losartan; Male; Midazolam; Middle Aged; Omeprazole; Young Adult | 2015 |
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Omeprazole; Warfarin; Young Adult | 2015 |
Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
Topics: Adult; Alkynes; Benzoxazines; Caffeine; Cross-Over Studies; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Genotype; Humans; Losartan; Male; Metoprolol; Midazolam; Omeprazole; Phenotype; Young Adult | 2016 |
A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.
Topics: Bayes Theorem; Caffeine; Computer Simulation; Dextromethorphan; Drug Interactions; Humans; Midazolam; Models, Biological; Omeprazole; Phenotype; Pilot Projects; Tolbutamide | 2016 |
Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.
Topics: Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Losartan; Male; Midazolam; Omeprazole; Plant Extracts; Rhodiola; Young Adult | 2016 |
Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Topics: Adolescent; Adult; Bupropion; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Dose-Response Relationship, Drug; Dried Blood Spot Testing; Drug Interactions; Female; Flurbiprofen; Genotyping Techniques; Humans; Male; Midazolam; Omeprazole; Phenotype; Terfenadine; Young Adult | 2016 |
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Imidazoles; Male; Midazolam; Middle Aged; Omeprazole; Pituitary ACTH Hypersecretion; Pyridines | 2017 |
Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.
Topics: Administration, Intravenous; Administration, Oral; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Drug Combinations; Fasting; Healthy Volunteers; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Time Factors; Warfarin; Young Adult | 2017 |
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Caffeine; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Midazolam; Middle Aged; Neoplasms; Omeprazole; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Tandem Mass Spectrometry; Warfarin | 2018 |
Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
Topics: Administration, Intravenous; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Fasting; Humans; Male; Metoprolol; Midazolam; Omeprazole; Pharmaceutical Preparations; Protein Binding; Warfarin | 2018 |
Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.
Topics: Adult; Area Under Curve; Caffeine; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Losartan; Male; Midazolam; Modafinil; Omeprazole; Phenotype; Time Factors; Young Adult | 2018 |
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Humans; Injections, Subcutaneous; Interleukin-23 Subunit p19; Male; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Treatment Outcome; Warfarin; Young Adult | 2018 |
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Topics: Antibodies, Monoclonal; Area Under Curve; Caffeine; Chronic Disease; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Injections, Subcutaneous; Male; Midazolam; Omeprazole; Psoriasis; Severity of Illness Index; Substrate Specificity; Warfarin | 2019 |
A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
Topics: Administration, Oral; Adult; Area Under Curve; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Dextromethorphan; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Losartan; Male; Midazolam; Middle Aged; Omeprazole; Piperidines; Pyridines; Young Adult | 2019 |
Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Male; Midazolam; Middle Aged; Omeprazole; Phenotype; Vitamin K; Warfarin | 2020 |
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Area Under Curve; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Omeprazole; Psoriasis; Severity of Illness Index; Warfarin; Young Adult | 2020 |
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Male; Metoprolol; Midazolam; Middle Aged; Neoplasms; Omeprazole; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides | 2020 |
Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities.
Topics: Administration, Oral; Adult; Area Under Curve; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Losartan; Male; Midazolam; Models, Biological; Omeprazole; Young Adult | 2021 |
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Bupropion; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Female; Flurbiprofen; Gene Expression Regulation; Half-Life; Healthy Volunteers; Humans; Male; Midazolam; Naphthoquinones; Neoplasm Proteins; Omeprazole; Rosuvastatin Calcium; Young Adult | 2021 |
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Topics: 5-Aminolevulinate Synthetase; Acetylgalactosamine; Adult; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activation; Female; Humans; Liver; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Omeprazole; Porphyrias, Hepatic; Pyrrolidines; RNA, Small Interfering | 2021 |
Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers.
Topics: Caffeine; China; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Omeprazole; Tolbutamide | 2022 |
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Midazolam; Middle Aged; Neoplasms; Omeprazole | 2023 |
80 other study(ies) available for omeprazole and midazolam
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
Topics: Cytochrome P-450 Enzyme Inhibitors; Enzyme Activation; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Molecular Structure; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
Topics: Administration, Oral; Animals; Arthritis; Cells, Cultured; Dimerization; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; Freund's Adjuvant; Humans; Lipopolysaccharides; Male; Mice; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type II; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; RAW 264.7 Cells; Structure-Activity Relationship | 2021 |
Inhibitory effect of omeprazole on the metabolism of midazolam in vitro.
Topics: Animals; Biotransformation; Chromatography, High Pressure Liquid; Humans; In Vitro Techniques; Male; Microsomes, Liver; Midazolam; Omeprazole; Oxidation-Reduction; Rats; Rats, Inbred Strains; Species Specificity | 1990 |
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Anti-Ulcer Agents; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Genotype; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating; Phenotype; Polymerase Chain Reaction; Xanthine Oxidase | 2000 |
Assessment of cytochrome P450 activity by a five-drug cocktail approach.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Male; Mephenytoin; Metoprolol; Midazolam; Mixed Function Oxygenases; Omeprazole; Oxidoreductases, N-Demethylating | 2001 |
A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes.
Topics: Biotransformation; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Flurbiprofen; Humans; Isoenzymes; Midazolam; Omeprazole; Phenotype; Reproducibility of Results; Sensitivity and Specificity | 2004 |
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Induction; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Injections, Intravenous; Intestinal Mucosa; Intestines; Liver; Lopinavir; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pyrimidinones; Ritonavir; Substrate Specificity; Warfarin | 2006 |
Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.
Topics: Adult; Anti-Ulcer Agents; Biomarkers; Brazil; Cytochrome P-450 CYP3A; Female; Humans; Male; Metabolic Clearance Rate; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenotype; Young Adult | 2008 |
A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients.
Topics: Biotransformation; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Losartan; Midazolam; Omeprazole; Phenotype; Tandem Mass Spectrometry | 2009 |
Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on cytochrome P450 activities in healthy volunteers.
Topics: Adult; Angelica; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Dextromethorphan; Drugs, Chinese Herbal; Herb-Drug Interactions; Humans; Losartan; Male; Midazolam; Omeprazole; Phytotherapy; Republic of Korea; Scutellaria baicalensis; Tandem Mass Spectrometry; Young Adult | 2009 |
In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran.
Topics: Aged; Anti-Ulcer Agents; Antitubercular Agents; Cyclopropanes; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Hepatocytes; Humans; Hypoglycemic Agents; Male; Microsomes, Liver; Midazolam; Middle Aged; Milnacipran; Omeprazole; Selective Serotonin Reuptake Inhibitors; Testosterone | 2009 |
Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoates; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Flurbiprofen; Humans; Hydrazines; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Pyrazoles; Receptors, Thrombopoietin | 2010 |
Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions.
Topics: Chromatography, Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Discovery; Drug Interactions; Drug Stability; High-Throughput Screening Assays; Humans; Midazolam; Omeprazole; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Temperature; Tolbutamide | 2010 |
Cocktail approach for in vivo phenotyping of 5 major CYP450 isoenzymes: development of an effective sampling, extraction, and analytical procedure and pilot study with comparative genotyping.
Topics: Adult; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Female; Genotype; Humans; Isoenzymes; Male; Midazolam; Omeprazole; Phenotype; Pilot Projects; Tandem Mass Spectrometry; Tolbutamide; Young Adult | 2012 |
Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Brassica; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochromes; Dextromethorphan; Enzyme Inhibitors; Herb-Drug Interactions; Liver; Metabolic Clearance Rate; Midazolam; Omeprazole; Rats; RNA, Messenger; Tolbutamide | 2012 |
Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs.
Topics: Administration, Oral; Animals; Biological Availability; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Humans; Injections, Intravenous; Male; Metoprolol; Midazolam; Models, Animal; Omeprazole; Substrate Specificity; Swine; Swine, Miniature; Tandem Mass Spectrometry; Warfarin | 2012 |
Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
Topics: Adult; Antibiotics, Antitubercular; Asian People; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Imidazoles; Losartan; Male; Midazolam; Omeprazole; Rifampin; Tetrazoles; Theophylline; Time Factors; Withholding Treatment | 2013 |
The effects of H2S on the activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in vivo in rat.
Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Activation; Enzyme Inhibitors; Half-Life; Hydrogen Sulfide; Male; Mass Spectrometry; Midazolam; Omeprazole; Rats; Rats, Sprague-Dawley; Tolbutamide | 2013 |
Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dextromethorphan; Drug Interactions; Fluconazole; Fluvoxamine; Ketoconazole; Losartan; Male; Midazolam; Omeprazole; Rats, Sprague-Dawley | 2014 |
Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Calibration; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Flurbiprofen; Half-Life; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2014 |
Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.
Topics: Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Computer Simulation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dextromethorphan; Drug Interactions; Female; Fluoxetine; Half-Life; Hepatocytes; Humans; Lovastatin; Male; Midazolam; Models, Statistical; Omeprazole; Stereoisomerism | 2014 |
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.
Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bupropion; Caffeine; Capsules; Carbonated Beverages; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Coffee; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Dried Blood Spot Testing; Enzyme Inhibitors; Feasibility Studies; Flurbiprofen; Humans; Isoenzymes; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenotype; Pilot Projects; Predictive Value of Tests; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine; Young Adult | 2014 |
Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation.
Topics: Administration, Oral; Age Factors; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Metoprolol; Microsomes, Liver; Midazolam; Models, Animal; Models, Biological; Omeprazole; Warfarin | 2015 |
Evaluation of the impact of Polygonum capitatum, a traditional Chinese herbal medicine, on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs.
Topics: Animals; Area Under Curve; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Liver; Male; Midazolam; Omeprazole; Plant Extracts; Polygonum; Rats; Rats, Sprague-Dawley; Tolbutamide | 2014 |
Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats.
Topics: Adjuvants, Anesthesia; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Erlotinib Hydrochloride; Hypoglycemic Agents; Limit of Detection; Male; Midazolam; Omeprazole; Pharmaceutical Preparations; Phenacetin; Protein Kinase Inhibitors; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tolbutamide | 2015 |
Effects of capsicine on rat cytochrome P450 isoforms CYP1A2, CYP2C19, and CYP3A4.
Topics: Administration, Oral; Animals; Capsaicin; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochromes; Drug Interactions; Male; Mass Spectrometry; Midazolam; Omeprazole; Phenacetin; Rats; Rats, Sprague-Dawley | 2015 |
Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling.
Topics: Administration, Intravenous; Administration, Oral; Animals; Caffeine; Cytochrome P-450 Enzyme System; Dextromethorphan; Humans; Macaca fascicularis; Microsomes, Liver; Midazolam; Models, Biological; Omeprazole; Pharmacokinetics; Warfarin | 2015 |
Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
Topics: Administration, Intravenous; Administration, Oral; Animals; Biological Availability; Caffeine; Callithrix; Chromatography, Liquid; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Humans; Intestine, Small; Liver; Metoprolol; Midazolam; Models, Animal; Omeprazole; Tandem Mass Spectrometry; Warfarin | 2016 |
[Study of change in activity of hepatic drug metabolism enzymes in rat model of chronic unpredictable mild stress].
Topics: Animals; Chlorzoxazone; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Depression; Dextromethorphan; Liver; Midazolam; Omeprazole; Rats; Stress, Physiological; Tandem Mass Spectrometry; Theophylline; Tolbutamide | 2015 |
Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling.
Topics: Animals; Cytochrome P-450 Enzyme System; Dogs; Humans; Metoprolol; Midazolam; Models, Biological; Omeprazole; Swine; Swine, Miniature; Warfarin | 2016 |
Effect of Evodiamine on CYP Enzymes in Rats by a Cocktail Method.
Topics: Administration, Oral; Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Herb-Drug Interactions; Liver; Male; Metoprolol; Midazolam; Omeprazole; Phenacetin; Quinazolines; Rats, Sprague-Dawley; Tolbutamide | 2016 |
Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling.
Topics: Animals; Caffeine; Chimera; Cytochrome P-450 Enzyme System; Dogs; Humans; Macaca fascicularis; Mice; Midazolam; Models, Biological; Omeprazole; Pharmaceutical Preparations; Pharmacokinetics; Swine; Swine, Miniature; Warfarin | 2016 |
Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.
Topics: Algorithms; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; GABA Modulators; Humans; Isoenzymes; Kinetics; Liver Neoplasms; Metabolic Clearance Rate; Microsomes, Liver; Midazolam; Omeprazole; Pharmaceutical Preparations; Proton Pump Inhibitors | 2016 |
A short-term high fat diet increases exposure to midazolam and omeprazole in healthy subjects.
Topics: Adult; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diet, High-Fat; Humans; Male; Midazolam; Omeprazole; Young Adult | 2016 |
Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
Topics: Animals; Caffeine; Constitutive Androstane Receptor; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Fasting; Female; Gene Expression Regulation; Inactivation, Metabolic; Liver; Membrane Proteins; Metoprolol; Mice; Mice, Inbred C57BL; Mice, Knockout; Midazolam; Omeprazole; Receptors, Cytoplasmic and Nuclear; Warfarin | 2016 |
Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Fermented Foods; Healthy Volunteers; Humans; Losartan; Male; Midazolam; Middle Aged; Omeprazole; Panax; Pharmaceutical Preparations; Terfenadine; Young Adult | 2016 |
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Metoprolol; Midazolam; Omeprazole; Rifampin; Substrate Specificity; Warfarin | 2018 |
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Chenodeoxycholic Acid; Cholangitis; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Omeprazole; Rosuvastatin Calcium; Warfarin | 2017 |
Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Caffeine; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P450 Family 2; Drugs, Chinese Herbal; Enzyme Activation; Herb-Drug Interactions; Isoenzymes; Midazolam; Omeprazole; Rats; Steroid 16-alpha-Hydroxylase; Tolbutamide; Warfarin | 2017 |
Evaluation of the metabolic capability of primary human hepatocytes in three-dimensional cultures on microstructural plates.
Topics: Acetaminophen; Adenosine Triphosphate; Arylsulfotransferase; Cell Culture Techniques; Cells, Cultured; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme System; Diclofenac; Glucuronosyltransferase; Hepatocytes; Humans; Lamotrigine; Midazolam; Omeprazole; Rifampin; RNA, Messenger; Triazines | 2018 |
Cytochrome P450-dependent drug oxidation activities in commercially available hepatocytes derived from human induced pluripotent stem cells cultured for 3 weeks.
Topics: Cells, Cultured; Cytochrome P-450 Enzyme System; Diclofenac; Hepatocytes; Humans; Hydroxylation; Induced Pluripotent Stem Cells; Isoenzymes; Midazolam; Omeprazole; Pregnane X Receptor; Receptors, Steroid; Time Factors | 2018 |
[Change of hepatic drug metabolism enzymes in rat depression model with kidney-yang deficiency].
Topics: Animals; Chlorzoxazone; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Depression; Dextromethorphan; Hydrocortisone; Liver; Midazolam; Omeprazole; Rats; Tandem Mass Spectrometry; Theophylline; Tolbutamide; Yang Deficiency | 2017 |
A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Liver-Specific Organic Anion Transporter 1; Losartan; Male; Midazolam; Omeprazole; Panax; Plant Preparations; Random Allocation; Young Adult | 2018 |
A UHPLC-MS/MS method coupled with liquid-liquid extraction for the quantitation of phenacetin, omeprazole, metoprolol, midazolam and their metabolites in rat plasma and its application to the study of four CYP450 activities.
Topics: Administration, Oral; Animals; Benzofurans; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Drug Interactions; Liquid-Liquid Extraction; Male; Metoprolol; Midazolam; Omeprazole; Phenacetin; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2019 |
LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Biological Variation, Population; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Healthy Volunteers; Humans; Isoenzymes; Losartan; Male; Metoprolol; Midazolam; Omeprazole; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Terfenadine | 2019 |
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
Topics: Administration, Oral; Adult; Caffeine; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Dextromethorphan; Down-Regulation; Drug Development; Drug Interactions; Female; Humans; Interleukin-6; Male; Midazolam; Middle Aged; Models, Biological; Neuromyelitis Optica; Omeprazole; Rare Diseases; Serum Albumin, Human; Simvastatin; Warfarin | 2019 |
Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation.
Topics: Adult; Asian People; Computer Simulation; Cytochrome P-450 Enzyme System; Female; Glucuronosyltransferase; Humans; Liver-Specific Organic Anion Transporter 1; Lorazepam; Male; Metoprolol; Midazolam; Middle Aged; Models, Biological; Omeprazole; Rosuvastatin Calcium; Software; Warfarin; Young Adult | 2019 |
Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4.
Topics: Alternative Splicing; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochromes b5; Genetic Variation; Humans; In Vitro Techniques; Liver; Midazolam; Omeprazole; Tolbutamide | 2019 |
Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Bupropion; Caffeine; Case-Control Studies; Chlorzoxazone; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Diabetes Mellitus, Type 2; Female; Humans; Interferon-gamma; Interleukin-1beta; Interleukin-6; Male; Midazolam; Middle Aged; Omeprazole; Tolbutamide; Tumor Necrosis Factor-alpha | 2019 |
An improved cytochrome P450 phenotyping cocktail with a simplified and highly sensitive UHPLC-MS/MS assay in human plasma.
Topics: Biosensing Techniques; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Limit of Detection; Losartan; Midazolam; Omeprazole; Phenotype; Sensitivity and Specificity; Tandem Mass Spectrometry | 2020 |
Calycosin Influences the Metabolism of Five Probe Drugs in Rats.
Topics: Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drugs, Chinese Herbal; Isoflavones; Medicine, Chinese Traditional; Metoprolol; Midazolam; Omeprazole; Phenacetin; Rats; Tolbutamide | 2020 |
Verification of a cocktail approach for quantitative drug-drug interaction assessment: a comparative analysis between the results of a single drug and a cocktail drug.
Topics: Cytochrome P-450 Enzyme System; Drug Interactions; Midazolam; Omeprazole; Pharmaceutical Preparations | 2021 |
Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates.
Topics: Antifungal Agents; Computer Simulation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Humans; Inflammation; Midazolam; Models, Biological; Omeprazole; Voriconazole | 2021 |
Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes.
Topics: Bupropion; Cytochrome P-450 Enzyme System; Diclofenac; Drug Evaluation, Preclinical; Ethanolamines; Hepatobiliary Elimination; Hepatocytes; Humans; Liver; Microsomes, Liver; Midazolam; Omeprazole; Proteome; Proteomics | 2021 |
Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Busulfan; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Midazolam; Models, Biological; Omeprazole; Pharmaceutical Preparations | 2022 |
Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein-disease-drug interaction in immune-mediated inflammatory diseases.
Topics: Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Midazolam; Models, Biological; Omeprazole; Warfarin | 2022 |
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Down-Regulation; Drug Interactions; Esomeprazole; Humans; Inflammation; Interleukin-6; Midazolam; Omeprazole | 2022 |
Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Fluconazole; Humans; Midazolam; Omeprazole; Rifampin; Sodium Bicarbonate; Yohimbine | 2022 |
Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
Topics: Caffeine; Child; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Flurbiprofen; Humans; Liver Cirrhosis; Metoprolol; Midazolam; Omeprazole | 2022 |
Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug.
Topics: Animals; Chlorzoxazone; Gastrointestinal Microbiome; Metoprolol; Mice; Midazolam; Non-alcoholic Fatty Liver Disease; Omeprazole; Pharmaceutical Preparations; Phenacetin; Tolbutamide | 2022 |
[Effect of Laportea bulbifera extract on CYP450 enzyme activities in rats by Cocktail probe drug method].
Topics: Animals; Caffeine; Chlorzoxazone; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Metoprolol; Midazolam; Omeprazole; Plant Extracts; Rats; Tandem Mass Spectrometry; Tolbutamide | 2022 |
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivo.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Factor Va; Humans; Male; Midazolam; Omeprazole | 2023 |
Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Topics: Adult; Caffeine; Cannabidiol; Cannabinoids; Cannabis; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dronabinol; Drug Interactions; Hallucinogens; Humans; Losartan; Midazolam; Omeprazole; Plant Extracts | 2023 |
Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Omeprazole; Warfarin | 2023 |
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Humans; Midazolam; Omeprazole; Rifampin; Tolbutamide; Tuberculosis, Pulmonary | 2023 |
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.
Topics: Adult; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Flurbiprofen; Healthy Volunteers; Humans; Midazolam; Omeprazole; Orexins | 2023 |